BioCentury
ARTICLE | Company News

Beyond Keytruda: Merck details plans for future growth

June 20, 2019 9:05 PM UTC

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes off patent in 2023.

Merck also highlighted China as a key growth driver and provided insight into its appetite for M&A...

BCIQ Company Profiles

Merck & Co. Inc.